Neuroproteomics and systems biology approach to identify temporal biomarker changes post experimental traumatic brain injury in rats

Frontiers in Neurology

Volumn 7, Issue NOV, 2016, Pages

  Kobeissy, Firas H ^a   Guingab Cagmat, Joy D ^b   Zhang, Zhiqun ^a   Moghieb, Ahmed ^a   Glushakova, Olena Y ^c   Mondello, Stefania ^d   Boutté, Angela M ^e   Anagli, John ^f,g   Rubenstein, Richard ^h   Bahmad, Hisham ^i,j   Wagner, Amy K ^k,l   Hayes, Ronald L ^a,c   Wang, Kevin K W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b BANYAN BIOMARKERS INC   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MESSINA   (Italy)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^f NeuroTheranostics Inc   (United States)

^g HENRY FORD HEALTH SYSTEM   (United States)

^h Downstate Health Sciences University   (United States)

ⁱ BEIRUT ARAB UNIVERSITY   (Lebanon)

^j AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^k UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

Biomarker; Controlled cortical impact; Inflammation; Oxidative stress; Prognosis and therapeutics; Proteomics; Traumatic brain injury

Indexed keywords

BIOLOGICAL MARKER; CALMODULIN; CASEIN KINASE; CASEIN KINASE SUBSTRATE IN NEURONS PROTEIN 1; CRYM PROTEIN; ELONGATION FACTOR 2; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE B CHAIN; LIPOCORTIN 5; NEUROFASCIN; PEPTIDYLPROLYL ISOMERASE PIN1; PROTEIN DISULFIDE ISOMERASE; PROTEIN KINASE C; PROTEOME; SUPEROXIDE DISMUTASE; THYROID HORMONE; UNCLASSIFIED DRUG; VINCULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; AXONAL GUIDANCE; BIOINFORMATICS; CELL FUNCTION; CELLULAR DISTRIBUTION; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL TRAUMATIC BRAIN INJURY; FEMALE; GENE ONTOLOGY; INFLAMMATION; ION EXCHANGE CHROMATOGRAPHY; MALE; NERVE FIBER GROWTH; NEUROPROTEOMICS; NONHUMAN; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEOMICS; RAT; REGENERATION; REVERSED PHASE LIQUID CHROMATOGRAPHY; SYSTEMS BIOLOGY; TANDEM MASS SPECTROMETRY; UPREGULATION;

EID: 85006085713     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2016.00198     Document Type: Article

References (104)

1. Pearson WS, Sugerman DE, McGuire LC, Coronado VG. Emergency department visits for traumatic brain injury in older adults in the United States: 2006-08. West J Emerg Med (2012) 13(3):289-93. doi:10.5811/westjem.2012.3.11559
2. Cuthbert JP, Harrison-Felix C, Corrigan JD, Kreider S, Bell JM, Coronado VG, et al. Epidemiology of adults receiving acute inpatient rehabilitation for a primary diagnosis of traumatic brain injury in the United States. J Head Trauma Rehabil (2014) 30(2):122-35. doi:10.1097/HTR.0000000000000012
3. Coronado VG, Xu L, Basavaraju SV, McGuire LC, Wald MM, Faul MD, et al. Surveillance for traumatic brain injury-related deaths-United States, 1997-2007. MMWR Surveill Summ (2011) 60(5):1-32.
4. Ling G, Bandak F, Armonda R, Grant G, Ecklund J. Explosive blast neurotrauma. J Neurotrauma (2009) 26(6):815-25. doi:10.1089/neu.2007.0484
5. Stocchetti N, Pagan F, Calappi E, Canavesi K, Beretta L, Citerio G, et al. Inaccurate early assessment of neurological severity in head injury. J Neurotrauma (2004) 21(9):1131-40. doi:10.1089/neu.2004.21.1131
6. Livingston BM, Mackenzie SJ, MacKirdy FN, Howie JC. Should the pre-sedation Glasgow Coma Scale value be used when calculating acute physiology and chronic health evaluation scores for sedated patients? Scottish Intensive Care Society Audit Group. Crit Care Med (2000) 28(2):389-94. doi:10.1097/00003246-200002000-00017
7. Marion DW, Carlier PM. Problems with initial Glasgow Coma Scale assessment caused by prehospital treatment of patients with head injuries: results of a national survey. J Trauma (1994) 36(1):89-95. doi:10.1097/00005373-199401000-00014
8. Corrigan JD. Substance abuse as a mediating factor in outcome from traumatic brain injury. Arch Phys Med Rehabil (1995) 76(4):302-9. doi:10.1016/S0003-9993(95)80654-7
9. Lindenbaum GA, Carroll SF, Daskal I, Kapusnick R. Patterns of alcohol and drug abuse in an urban trauma center: the increasing role of cocaine abuse. J Trauma (1989) 29(12):1654-8. doi:10.1097/00005373-198912000-00012
10. Taylor LA, Kreutzer JS, Demm SR, Meade MA. Traumatic brain injury and substance abuse: a review and analysis of the literature. Neuropsychol Rehabil (2003) 13(1-2):165-88. doi:10.1080/09602010244000336
11. Levi L, Guilburd JN, Lemberger A, Soustiel JF, Feinsod M. Diffuse axonal injury: analysis of 100 patients with radiological signs. Neurosurgery (1990) 27(3):429-32. doi:10.1227/00006123-199009000-00015
12. Kesler SR, Adams HF, Bigler ED. SPECT, MR and quantitative MR imaging: correlates with neuropsychological and psychological outcome in traumatic brain injury. Brain Inj (2000) 14(10):851-7. doi:10.1080/026990500445682
13. Pike BR, Flint J, Dutta S, Johnson E, Wang KK, Hayes RL. Accumulation of non-erythroid alpha II-spectrin and calpain-cleaved alpha II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats. J Neurochem (2001) 78(6):1297-306. doi:10.1046/j.1471-4159.2001.00510.x
14. Pike BR, Zhao X, Newcomb JK, Posmantur RM, Wang KK, Hayes RL. Regional calpain and caspase-3 proteolysis of alpha-spectrin after traumatic brain injury. Neuroreport (1998) 9(11):2437-42. doi:10.1097/00001756-199808030-00002
15. Ringger NC, O'Steen BE, Brabham JG, Silver X, Pineda J, Wang KK, et al. A novel marker for traumatic brain injury: CSF alphaII-spectrin breakdown product levels. J Neurotrauma (2004) 21(10):1443-56. doi:10.1089/neu.2004.21.1443
16. Glushakova OY, Johnson D, Hayes RL. Delayed increases in microvascular pathology after experimental traumatic brain injury are associated with prolonged inflammation, blood-brain barrier disruption, and progressive white matter damage. J Neurotrauma (2014) 31(13):1180-93. doi:10.1089/neu.2013.3080
17. Raabe A, Kopetsch O, Woszczyk A, Lang J, Gerlach R, Zimmermann M, et al. Serum S-100B protein as a molecular marker in severe traumatic brain injury. Restor Neurol Neurosci (2003) 21(3-4):159-69.
18. Berger RP, Adelson PD, Pierce MC, Dulani T, Cassidy LD, Kochanek PM. Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg (2005) 103(1 Suppl):61-8. doi:10.3171/ped.2005.103.1.0061
19. Mondello S, Kobeissy F, Vestri A, Hayes RL, Kochanek PM, Berger RP. Serum concentrations of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein after pediatric traumatic brain injury. Sci Rep (2016) 6:28203. doi:10.1038/srep28203
20. Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Clark RS, Ruppel RA, et al. Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatrics (2002) 109(2):E31. doi:10.1542/peds.109.2.e31
21. Niyonkuru C, Wagner AK, Ozawa H, Amin K, Goyal A, Fabio A. Group-based trajectory analysis applications for prognostic biomarker model development in severe TBI: a practical example. J Neurotrauma (2013) 30(11):938-45. doi:10.1089/neu.2012.2578
22. Goyal A, Failla MD, Niyonkuru C, Amin K, Fabio A, Berger RP, et al. S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury. J Neurotrauma (2013) 30(11):946-57. doi:10.1089/neu.2012.2579
23. Zemlan FP, Jauch EC, Mulchahey JJ, Gabbita SP, Rosenberg WS, Speciale SG, et al. C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome. Brain Res (2002) 947(1):131-9. doi:10.1016/S0006-8993(02)02920-7
24. Rubenstein R, Chang B, Davies P, Wagner AK, Robertson CS, Wang KK. A novel, ultrasensitive assay for tau: potential for assessing traumatic brain injury in tissues and biofluids. J Neurotrauma (2015) 32(5):342-52. doi:10.1089/neu.2014.3548
25. Guingab-Cagmat JD, Kobeissy F, Ratliff MV, Shi P, Zhang Z, Wang KW. Neurogenomics and neuroproteomics approaches of studying neural injury. In: Fehlings M, editors. Essentials of Spinal Cord Injury. Toronto: Thieme (2010) 605-18.
26. Kobeissy FH, Ottens AK, Zhang Z, Liu MC, Denslow ND, Dave JR, et al. Novel differential neuroproteomics analysis of traumatic brain injury in rats. Mol Cell Proteomics (2006) 5(10):1887-98. doi:10.1074/mcp.M600157-MCP200
27. Ottens AK, Kobeissy FH, Fuller BF, Liu MC, Oli MW, Hayes RL, et al. Novel neuroproteomic approaches to studying traumatic brain injury. Prog Brain Res (2007) 161:401-18. doi:10.1016/S0079-6123(06)61029-7
28. Ottens AK, Kobeissy FH, Golden EC, Zhang Z, Haskins WE, Chen SS, et al. Neuroproteomics in neurotrauma. Mass Spectrom Rev (2006) 25(3):380-408. doi:10.1002/mas.20073
29. Kochanek AR, Kline AE, Gao WM, Chadha M, Lai Y, Clark RS, et al. Gel-based hippocampal proteomic analysis 2 weeks following traumatic brain injury to immature rats using controlled cortical impact. Dev Neurosci (2006) 28(4-5):410-9. doi:10.1159/000094167
30. Haskins WE, Kobeissy FH, Wolper RA, Ottens AK, Kitlen JW, McClung SH, et al. Rapid discovery of putative protein biomarkers of traumatic brain injury by SDS-PAGE-capillary liquid chromatography-tandem mass spectrometry. J Neurotrauma (2005) 22(6):629-44. doi:10.1089/neu.2005.22.629
31. Agoston DV, Gyorgy A, Eidelman O, Pollard HB. Proteomic biomarkers for blast neurotrauma: targeting cerebral edema, inflammation, and neuronal death cascades. J Neurotrauma (2009) 26(6):901-11. doi:10.1089/neu.2008.0724
32. Ekegren T, Hanrieder J, Bergquist J. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research. J Mass Spectrom (2008) 43(5):559-71. doi:10.1002/jms.1409
33. Prieto DA, Ye X, Veenstra TD. Proteomic analysis of traumatic brain injury: the search for biomarkers. Expert Rev Proteomics (2008) 5(2):283-91. doi:10.1586/14789450.5.2.283
34. Chen A, Liao WP, Lu Q, Wong WS, Wong PT. Upregulation of dihydropyrimidinase-related protein 2, spectrin alpha II chain, heat shock cognate protein 70 pseudogene 1 and tropomodulin 2 after focal cerebral ischemia in rats-a proteomics approach. Neurochem Int (2007) 50(7-8):1078-86. doi:10.1016/j.neuint.2006.11.008
35. Abou-Abbass H, Bahmad H, Abou-El-Hassan H, Zhu R, Zhou S, Dong X, et al. Deciphering glycomics and neuroproteomic alterations in experimental traumatic brain injury: comparative analysis of aspirin and clopidogrel treatment. Electrophoresis (2016) 37(11):1562-76. doi:10.1002/elps.201500583
36. Afjehi-Sadat L, Brejnikow M, Kang SU, Vishwanath V, Walder N, Herkner K, et al. Differential protein levels and post-translational modifications in spinal cord injury of the rat. J Proteome Res (2010) 9(3):1591-7. doi:10.1021/pr901049a
37. Chen A, McEwen ML, Sun S, Ravikumar R, Springer JE. Proteomic and phosphoproteomic analyses of the soluble fraction following acute spinal cord contusion in rats. J Neurotrauma (2010) 27(1):263-74. doi:10.1089/neu.2009.1051
38. Chen A, Springer JE. Neuroproteomic methods in spinal cord injury. Methods Mol Biol (2009) 566:57-67. doi:10.1007/978-1-59745-562-6_4
39. Ding Q, Wu Z, Guo Y, Zhao C, Jia Y, Kong F, et al. Proteome analysis of up-regulated proteins in the rat spinal cord induced by transection injury. Proteomics (2006) 6(2):505-18. doi:10.1002/pmic.200500296
40. Kang SK, So HH, Moon YS, Kim CH. Proteomic analysis of injured spinal cord tissue proteins using 2-DE and MALDI-TOF MS. Proteomics (2006) 6(9):2797-812. doi:10.1002/pmic.200500621
41. Katano T, Mabuchi T, Okuda-Ashitaka E, Inagaki N, Kinumi T, Ito S. Proteomic identification of a novel isoform of collapsin response mediator protein-2 in spinal nerves peripheral to dorsal root ganglia. Proteomics (2006) 6(22):6085-94. doi:10.1002/pmic.200600300
42. Singh OV, Yaster M, Xu JT, Guan Y, Guan X, Dharmarajan AM, et al. Proteome of synaptosome-associated proteins in spinal cord dorsal horn after peripheral nerve injury. Proteomics (2009) 9(5):1241-53. doi:10.1002/pmic.200800636
43. Yan X, Liu J, Luo Z, Ding Q, Mao X, Yan M, et al. Proteomic profiling of proteins in rat spinal cord induced by contusion injury. Neurochem Int (2010) 56(8):971-83. doi:10.1016/j.neuint.2010.04.007
44. Devaux S, Cizkova D, Quanico J, Franck J, Nataf S, Pays L, et al. Proteomic analysis of the spatio-temporal based molecular kinetics of acute spinal cord injury identifies a time-and segment-specific window for effective tissue repair. Mol Cell Proteomics (2016) 15(8):2641-70. doi:10.1074/mcp.M115.057794
45. Ottens AK, Bustamante L, Golden EC, Yao C, Hayes RL, Wang KK, et al. Neuroproteomics: a biochemical means to discriminate the extent and modality of brain injury. J Neurotrauma (2010) 27(10):1837-52. doi:10.1089/neu.2010.1374
46. Zhang G, Wang F, Geng M, Chen L. [Comparative proteomic analysis of hippocampus between chronic cerebral ischemia rats and normal controls]. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2011) 36(10):992-8. doi:10.3969/j.issn.1672-7347.2011.10.010
47. Liu B, Tewari AK, Zhang L, Green-Church KB, Zweier JL, Chen YR, et al. Proteomic analysis of protein tyrosine nitration after ischemia reperfusion injury: mitochondria as the major target. Biochim Biophys Acta (2009) 1794(3):476-85. doi:10.1016/j.bbapap.2008.12.008
48. Junker H, Suofu Y, Venz S, Sascau M, Herndon JG, Kessler C, et al. Proteomic identification of an upregulated isoform of annexin A3 in the rat brain following reversible cerebral ischemia. Glia (2007) 55(16):1630-7. doi:10.1002/glia.20581
49. Cid C, Garcia-Bonilla L, Camafeita E, Burda J, Salinas M, Alcazar A. Proteomic characterization of protein phosphatase 1 complexes in ischemia-reperfusion and ischemic tolerance. Proteomics (2007) 7(17):3207-18. doi:10.1002/pmic.200700214
50. Ren C, Kobeissy F, Alawieh A, Li N, Li N, Zibara K, et al. Assessment of serum UCH-L1 and GFAP in acute stroke patients. Sci Rep (2016) 6:24588. doi:10.1038/srep24588
51. Ottens AK. The methodology of neuroproteomics. Methods Mol Biol (2009) 566:1-21. doi:10.1007/978-1-59745-562-6_1
52. Ottens AK, Kobeissy FH, Wolper RA, Haskins WE, Hayes RL, Denslow ND, et al. A multidimensional differential proteomic platform using dual-phase ion-exchange chromatography-polyacrylamide gel electrophoresis/reversed-phase liquid chromatography tandem mass spectrometry. Anal Chem (2005) 77(15):4836-45. doi:10.1021/ac050478r
53. Moghieb A, Bramlett HM, Das JH, Yang Z, Selig T, Yost RA, et al. Differential Neuroproteomic and systems biology analysis of spinal cord injury. Mol Cell Proteomics (2016) 15(7):2379-95. doi:10.1074/mcp.M116.058115
54. Yuryev A, Kotelnikova E, Daraselia N. Ariadne's ChemEffect and Pathway Studio knowledge base. Expert Opin Drug Discov (2009) 4(12):1307-18. doi:10.1517/17460440903413488
55. Bonnet A, Lagarrigue S, Liaubet L, Robert-Granié C, Sancristobal M, Tosser-Klopp G. Pathway results from the chicken data set using GOTM, Pathway Studio and Ingenuity softwares. BMC Proc (2009) 3(Suppl 4):S11. doi:10.1186/1753-6561-3-S4-S11
56. Heberle H, Meirelles GV, da Silva FR, Telles GP, Minghim R. InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. BMC Bioinformatics (2015) 16:169. doi:10.1186/s12859-015-0611-3
57. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med (2006) 3(11):e442. doi:10.1371/journal.pmed.0030442
58. Kobeissy FH, Guingab-Cagmat JD, Razafsha M, O'Steen L, Zhang Z, Hayes RL, et al. Leveraging biomarker platforms and systems biology for rehabilomics and biologics effectiveness research. PM R (2011) 3(6 Suppl 1):S139-47. doi:10.1016/j.pmrj.2011.02.012
59. Truettner JS, Suzuki T, Dietrich WD. The effect of therapeutic hypothermia on the expression of inflammatory response genes following moderate traumatic brain injury in the rat. Brain Res Mol Brain Res (2005) 138(2):124-34. doi:10.1016/j.molbrainres.2005.04.006
60. Popp J, Bacher M, Kölsch H, Noelker C, Deuster O, Dodel R, et al. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. J Psychiatr Res (2009) 43(8):749-53. doi:10.1016/j.jpsychires.2008.10.006
61. Mackensen GB, Patel M, Sheng H, Calvi CL, Batinic-Haberle I, Day BJ, et al. Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant. J Neurosci (2001) 21(13):4582-92.
62. Gardner PR. Aconitase: sensitive target and measure of superoxide. Methods Enzymol (2002) 349:9-23. doi:10.1016/S0076-6879(02)49317-2
63. Yunoki M, Kawauchi M, Ukita N, Sugiura T, Ohmoto T. Effects of lecithinized superoxide dismutase on neuronal cell loss in CA3 hippocampus after traumatic brain injury in rats. Surg Neurol (2003) 59(3):156-60; discussion 160-1. doi:10.1016/S0090-3019(02)01040-6
64. Yunoki M, Kawauchi M, Ukita N, Noguchi Y, Nishio S, Ono Y, et al. Effects of lecithinized superoxide dismutase on traumatic brain injury in rats. J Neurotrauma (1997) 14(10):739-46. doi:10.1089/neu.1997.14.739
65. Ding K, Wang H, Xu J, Li T, Zhang L, Ding Y, et al. Melatonin stimulates antioxidant enzymes and reduces oxidative stress in experimental traumatic brain injury: the Nrf2-ARE signaling pathway as a potential mechanism. Free Radic Biol Med (2014) 73:1-11. doi:10.1016/j.freeradbiomed.2014.04.031
66. Lewen A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma (2000) 17(10):871-90. doi:10.1089/neu.2000.17.871
67. Thompson JS, Chu Y, Glass J, Tapp AA, Brown SA. The manganese superoxide dismutase mimetic, M40403, protects adult mice from lethal total body irradiation. Free Radic Res (2010) 44(5):529-40. doi:10.3109/10715761003649578
68. Zhang Z, Kobeissy FH, Ottens AK, Martínez JA, Wang KK. Calmodulin-binding proteome in the brain. Methods Mol Biol (2009) 566:181-90. doi:10.1007/978-1-59745-562-6_12
69. Atkins CM, Chen S, Alonso OF, Dietrich WD, Hu BR. Activation of calcium/calmodulin-dependent protein kinases after traumatic brain injury. J Cereb Blood Flow Metab (2006) 26(12):1507-18. doi:10.1038/sj.jcbfm.9600301
70. Bales JW, Ma X, Yan HQ, Jenkins LW, Dixon CE. Expression of protein phosphatase 2B (calcineurin) subunit A isoforms in rat hippocampus after traumatic brain injury. J Neurotrauma (2010) 27(1):109-20. doi:10.1089/neu.2009.1072
71. Sewell DL, Nacewicz B, Liu F, Macvilay S, Erdei A, Lambris JD, et al. Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. J Neuroimmunol (2004) 155(1-2):55-63. doi:10.1016/j.jneuroim.2004.06.003
72. Rostami E, Davidsson J, Gyorgy A, Agoston DV, Risling M, Bellander BM. The terminal pathway of the complement system is activated in focal penetrating but not in mild diffuse traumatic brain injury. J Neurotrauma (2013) 30(23):1954-65. doi:10.1089/neu.2012.2583
73. Al Nimer F, Lindblom R, Ström M, Guerreiro-Cacais AO, Parsa R, Aeinehband S, et al. Strain influences on inflammatory pathway activation, cell infiltration and complement cascade after traumatic brain injury in the rat. Brain Behav Immun (2013) 27(1):109-22. doi:10.1016/j.bbi.2012.10.002
74. Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature (1999) 399(6738):784-8. doi:10.1038/21650
75. Liou YC, Sun A, Ryo A, Zhou XZ, Yu ZX, Huang HK, et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature (2003) 424(6948):556-61. doi:10.1038/nature01832
76. Takahashi K, Shimizu T, Kosaka K, Hidaka M, Uchida C, Uchida T. Role of prolyl isomerase pin1 in pathogenesis of diseases and remedy for the diseases from natural products. Curr Drug Targets (2014) 15(10):973-81. doi:10.2174/1389450115666140903110724
77. Arosio B, Segat L, Milanese M, Galimberti L, Calabresi C, Zanetti M, et al. PIN-1 promoter polymorphisms in mild cognitive impairment and susceptibility to Alzheimer's disease: a preliminary report. Aging Clin Exp Res (2007) 19(5):406-9. doi:10.1007/BF03324722
78. Butterfield DA, Abdul HM, Opii W, Newman SF, Joshi G, Ansari MA, et al. Pin1 in Alzheimer's disease. J Neurochem (2006) 98(6):1697-706. doi:10.1111/j.1471-4159.2006.03995.x
79. Abou-Abbass H, Abou-El-Hassan H, Bahmad H, Zibara K, Zebian A, Youssef R, et al. Glycosylation and other PTMs alterations in neurodegenerative diseases: current status and future role in neurotrauma. Electrophoresis (2016) 37(11):1549-61. doi:10.1002/elps.201500585
80. Yao G, Su X, Nguyen V, Roberts K, Li X, Takakura A, et al. Polycystin-1 regulates actin cytoskeleton organization and directional cell migration through a novel PC1-Pacsin 2-N-Wasp complex. Hum Mol Genet (2014) 23(10):2769-79. doi:10.1093/hmg/ddt672
81. Grimm-Günter EM, Milbrandt M, Merkl B, Paulsson M, Plomann M. PACSIN proteins bind tubulin and promote microtubule assembly. Exp Cell Res (2008) 314(10):1991-2003. doi:10.1016/j.yexcr.2008.03.015
82. Plomann M, Lange R, Vopper G, Cremer H, Heinlein UA, Scheff S, et al. PACSIN, a brain protein that is upregulated upon differentiation into neuronal cells. Eur J Biochem (1998) 256(1):201-11. doi:10.1046/j.1432-1327.1998.2560201.x
83. Schael S, Nüchel J, Müller S, Petermann P, Kormann J, Pérez-Otaño I, et al. Casein kinase 2 phosphorylation of protein kinase C and casein kinase 2 substrate in neurons (PACSIN) 1 protein regulates neuronal spine formation. J Biol Chem (2013) 288(13):9303-12. doi:10.1074/jbc.M113.461293
84. Bai X, Zheng X. Tip-to-tip interaction in the crystal packing of PACSIN 2 is important in regulating tubulation activity. Protein Cell (2013) 4(9):695-701. doi:10.1007/s13238-013-3041-x
85. Billcliff PG, Noakes CJ, Mehta ZB, Yan G, Mak L, Woscholski R, et al. OCRL1 engages with the F-BAR protein pacsin 2 to promote biogenesis of membrane-trafficking intermediates. Mol Biol Cell (2016) 27(1):90-107. doi:10.1091/mbc.E15-06-0329
86. Takano M, Yamashita T, Nagano K, Otani M, Maekura K, Kamada H, et al. Proteomic analysis of the hippocampus in Alzheimer's disease model mice by using two-dimensional fluorescence difference in gel electrophoresis. Neurosci Lett (2013) 534:85-9. doi:10.1016/j.neulet.2012.11.010
87. Lizhnyak PN, Ottens AK. Proteomics: in pursuit of effective traumatic brain injury therapeutics. Expert Rev Proteomics (2015) 12(1):75-82. doi:10.1586/14789450.2015.1000869
88. Kalman M, Szabo A. Immunohistochemical investigation of actin-anchoring proteins vinculin, talin and paxillin in rat brain following lesion: a moderate reaction, confined to the astroglia of brain tracts. Exp Brain Res (2001) 139(4):426-34. doi:10.1007/s002210100789
89. Tanaka S, Uehara T, Nomura Y. Up-regulation of protein-disulfide isomerase in response to hypoxia/brain ischemia and its protective effect against apoptotic cell death. J Biol Chem (2000) 275(14):10388-93. doi:10.1074/jbc.275.14.10388
90. Bouter A, Carmeille R, Gounou C, Bouvet F, Degrelle SA, Evain-Brion D, et al. Review: annexin-A5 and cell membrane repair. Placenta (2015) 36(Suppl 1):S43-9. doi:10.1016/j.placenta.2015.01.193
91. Ross JM, Öberg J, Brené S, Coppotelli G, Terzioglu M, Pernold K, et al. High brain lactate is a hallmark of aging and caused by a shift in the lactate dehydrogenase A/B ratio. Proc Natl Acad Sci U S A (2010) 107(46):20087-92. doi:10.1073/pnas.1008189107
92. Hallen A, Jamie JF, Cooper AJ. Lysine metabolism in mammalian brain: an update on the importance of recent discoveries. Amino Acids (2013) 45(6):1249-72. doi:10.1007/s00726-013-1590-1
93. Delange F. The role of iodine in brain development. Proc Nutr Soc (2000) 59(1):75-9. doi:10.1017/S0029665100000094
94. Bernal J. Iodine and brain development. Biofactors (1999) 10(2-3):271-6. doi:10.1002/biof.5520100227
95. Argüelles S, Camandola S, Hutchison ER, Cutler RG, Ayala A, Mattson MP. Molecular control of the amount, subcellular location, and activity state of translation elongation factor 2 in neurons experiencing stress. Free Radic Biol Med (2013) 61:61-71. doi:10.1016/j.freeradbiomed.2013.03.016
96. Braciak TA, Northemann W, Hudson GO, Shiels BR, Gehring MR, Fey GH. Sequence and acute phase regulation of rat alpha 1-inhibitor III messenger RNA. J Biol Chem (1988) 263(8):3999-4012.
97. Hattori T, Takei N, Mizuno Y, Kato K, Kohsaka S. Neurotrophic and neuroprotective effects of neuron-specific enolase on cultured neurons from embryonic rat brain. Neurosci Res (1995) 21(3):191-8. doi:10.1016/0168-0102(94)00849-B
98. Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga SM. Neuroprotective function of DJ-1 in Parkinson's disease. Oxid Med Cell Longev (2013) 2013:683920. doi:10.1155/2013/683920
99. Smith DH, Hicks RR, Johnson VE, Bergstrom DA, Cummings DM, Noble LJ, et al. Pre-clinical traumatic brain injury common data elements: toward a common language across laboratories. J Neurotrauma (2015) 32(22):1725-35. doi:10.1089/neu.2014.3861
100. Kumar RG, Boles JA, Wagner AK. Chronic inflammation after severe traumatic brain injury: characterization and associations with outcome at 6 and 12 months postinjury. J Head Trauma Rehabil (2015) 30(6):369-81. doi:10.1097/HTR.0000000000000067
101. Kobeissy FH, Liu MC, Yang Z, Zhang Z, Zheng W, Glushakova O, et al. Degradation of betaII-spectrin protein by calpain-2 and caspase-3 under neurotoxic and traumatic brain injury conditions. Mol Neurobiol (2015) 52(1):696-709. doi:10.1007/s12035-014-8898-z
102. Liu MC, Akinyi L, Scharf D, Mo J, Larner SF, Muller U, et al. Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats. Eur J Neurosci (2010) 31(4):722-32. doi:10.1111/j.1460-9568.2010.07097.x
103. Zhang Z, Larner SF, Liu MC, Zheng W, Hayes RL, Wang KK. Multiple alphaII-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways. Apoptosis (2009) 14(11):1289-98. doi:10.1007/s10495-009-0405-z
104. Reeves TM, Greer JE, Vanderveer AS, Phillips LL. Proteolysis of submembrane cytoskeletal proteins ankyrin-G and alphaII-spectrin following diffuse brain injury: a role in white matter vulnerability at Nodes of Ranvier. Brain Pathol (2010) 20(6):1055-68. doi:10.1111/j.1750-3639.2010.00412.x